非小细胞肺癌3种化疗方案的最小成本分析

Cost-minimization analysis of three chemotherapy schemes for non-small cell lung cancer

目的比较非小细胞肺癌3种化疗方案的成本、临床疗效和不良反应,运用方案药物经济学方法进行最小成本分析。方法收集115例住院化疗患者的住院费用、临床疗效和化疗不良反应情况,比较NP和GP方案、DP方案的药物经济学指标。结果各组临床疗效和药物不良反应发生率之间差异无统计学意义。通过最小成本分析和敏感度分析显示,NP组优于GP组和DP组;DP组用于治疗药物不良反应的药费高于GP组,DP组ΔADR药费/Δ不良反应发生率(ΔC/ΔE)的值显著高于GP组(P<0.05)。结论根据药物经济学评价,NP方案为最经济方案,GP方案优于DP方案。

AIM To compare the cost-effectiveness of three antibacterial drugs in the treatment of lower respiratory tract infection. METHODS A total of 126 patients with lower respiratory tract infection were divided into 3 groups （group A, group B and group C）. Group A was given 1.5 g cefuroxime sodium, iv gtt, tid, group B was given 2.0 g ceftriaxone sodium, iv gtt, qd and group C was given 2.0 g cefoperazone sodium, iv gtt, bid, for 7d. RESULTS The effective rate in 3 groups was not significantly different （P 〉 0.05）. The therapeutic costs were 760.20 CNY, 701.40 CNY and 1 128.40 CNY, respectively. The cost-effectiveness ratio were 9.12,8.34 and 13.68,respectively. CONCLUSION Ceftriaxone sodium is the best choice for the treatment of lower respiratory tract infecion.